Literature DB >> 12720121

Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Donna Weber1, Steven P Treon, Christos Emmanouilides, Andrew R Branagan, John C Byrd, Joan Bladé, Eva Kimby.   

Abstract

Waldenstrom's macroglobulinemia (WM) is a malignant disorder of lymphoplasmacytic cells that produce a monoclonal immunoglobulin M (IgM). Since the original description by Jan Waldenström of three patients with symptoms of hyperviscosity due to circulating monoclonal IgM, the definition of WM has been controversial. Standardized criteria for diagnosis have now been proposed, including the presence of any IgM monoclonal protein and marrow and/or nodal lymphoplasmacytic cells. Although previous response criteria have generally incorporated parameters for monoclonal protein reduction and/or improvement of marrow/nodal involvement, specific and uniform response criteria are needed to facilitate comparisons of response, remission duration, progression-free survival, and overall survival in clinical trials similar to those previously established for other diseases such as chronic lymphocytic leukemia, lymphoma, and myeloma. This is of particular importance as new agents are developed and evaluated. This presentation represents consensus recommendations for uniform response criteria for use in assessing responses to treatment for patients with WM, which were prepared in conjunction with the Second International Workshop held in Athens, Greece during September 2002. Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720121     DOI: 10.1053/sonc.2003.50037

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  10 in total

1.  Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.

Authors:  Morie A Gertz; Rafat Abonour; Leonard T Heffner; Philip R Greipp; Hajime Uno; S V Rajkumar
Journal:  Br J Haematol       Date:  2009-09-14       Impact factor: 6.998

2.  Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.

Authors:  Beata Holkova; E Brent Perkins; Viswanathan Ramakrishnan; Mary Beth Tombes; Ellen Shrader; Neha Talreja; Martha D Wellons; Kevin T Hogan; G David Roodman; Domenico Coppola; Loveleen Kang; Jana Dawson; Robert K Stuart; Cody Peer; William D Figg; Sarah Kolla; Austin Doyle; John Wright; Daniel M Sullivan; John D Roberts; Steven Grant
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

3.  New Therapeutic Approaches for Waldenstrom Macroglobulinemia.

Authors:  Jennifer Stedman; Aldo Roccaro; Xavier Leleu; Irene M Ghobrial
Journal:  Drugs Future       Date:  2010-01       Impact factor: 0.148

4.  Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.

Authors:  Irene M Ghobrial; Morie Gertz; Betsy Laplant; John Camoriano; Suzanne Hayman; Martha Lacy; Stacey Chuma; Brianna Harris; Renee Leduc; Meghan Rourke; Stephen M Ansell; Daniel Deangelo; Angela Dispenzieri; Leif Bergsagel; Craig Reeder; Kenneth C Anderson; Paul G Richardson; Steven P Treon; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

5.  Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.

Authors:  Richard R Furman; Herbert A Eradat; Christine G DiRienzo; Craig C Hofmeister; Suzanne R Hayman; John P Leonard; Morton Coleman; Ranjana Advani; Asher Chanan-Khan; Julie Switzky; Qiming M Liao; Damini Shah; Roxanne C Jewell; Steen Lisby; Thomas S Lin
Journal:  Lancet Haematol       Date:  2016-12-01       Impact factor: 18.959

6.  Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.

Authors:  Beata Holkova; Maciej Kmieciak; E Brent Perkins; Prithviraj Bose; Rachid C Baz; G David Roodman; Robert K Stuart; Viswanathan Ramakrishnan; Wen Wan; Cody J Peer; Jana Dawson; Loveleen Kang; Connie Honeycutt; Mary Beth Tombes; Ellen Shrader; Caryn Weir-Wiggins; Martha Wellons; Heidi Sankala; Kevin T Hogan; A Dimitrios Colevas; L Austin Doyle; William D Figg; Domenico Coppola; John D Roberts; Daniel Sullivan; Steven Grant
Journal:  Clin Cancer Res       Date:  2014-09-23       Impact factor: 12.531

7.  Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.

Authors:  Mohamed A Kharfan-Dabaja; Claudio Anasetti; Hugo F Fernandez; Janelle Perkins; Jose L Ochoa-Bayona; Joseph Pidala; Lia E Perez; Ernesto Ayala; Teresa Field; Melissa Alsina; Taiga Nishihori; Frederick Locke; Javier Pinilla-Ibarz; Marcie Tomblyn
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-28       Impact factor: 5.742

8.  Waldenstrom macroglobulinemia.

Authors:  Xavier Leleu; Aldo M Roccaro; Anne-Sophie Moreau; Sophie Dupire; Daniela Robu; Julie Gay; Evdoxia Hatjiharissi; Nicholas Burwik; Irene M Ghobrial
Journal:  Cancer Lett       Date:  2008-06-13       Impact factor: 8.679

9.  Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.

Authors:  Irene M Ghobrial; Aldo Roccaro; Fangxin Hong; Edie Weller; Nancy Rubin; Renee Leduc; Meghan Rourke; Stacey Chuma; Antonio Sacco; Xiaoying Jia; Feda Azab; Abdel Kareem Azab; Scott Rodig; Diane Warren; Brianna Harris; Lyuba Varticovski; Peter Sportelli; Xavier Leleu; Kenneth C Anderson; Paul G Richardson
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

Review 10.  Waldenstrom macroglobulinemia: prognosis and management.

Authors:  A Oza; S V Rajkumar
Journal:  Blood Cancer J       Date:  2015-03-27       Impact factor: 11.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.